CAI News
Archived Headlines
- Oncology precision medicine platform Caris Life Sciences raises range to $19 to $20 ahead of $459 million IPO 06/16/25
- US IPO Week Ahead: Precision medicine and insurance IPOs take on the short holiday week 06/13/25
- Oncology precision medicine platform Caris Life Sciences sets terms for $400 million IPO 06/09/25
- Renaissance Capital's May IPO Market Update 06/02/25
- US IPO Weekly Recap: Year's first VC-backed tech IPO MNTN gains 73% 05/23/25
See more
Renaissance IPO Index – Notice of September 2025 Quarterly Changes
The Renaissance IPO Index, the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes effective Monday, September 22, 2025: Additions: Bullish Caris Life Sciences Chime Financial Circle Internet Group...read more
Updated: Renaissance Capital's 2Q 2025 US IPO Market Review
IPO Market Gains Traction in the 2Q Despite Tariff Turmoil Despite an early surge in volatility from shifting US tariff policies and recession concerns, the IPO market ended the quarter with more momentum than it started. A total of 44 IPOs raised a combined...read more
US IPO Weekly Recap: Sizable precision medicine and insurance IPOs raise a combined $902 million
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Precision medicine platform Caris Life Sciences (CAI) priced above the upwardly revised range to raise $494 million at a $6.1 billion market cap. Caris is...read more
Caris Life Sciences prices IPO at $21, above the upwardly revised range
Caris Life Sciences, which offers an AI-powered molecular diagnostics platform focused on oncology, raised $494 million by offering 23.5 million shares at $21, above the upwardly revised range of $19 to $20. The company had originally planned to offer the same...read more